Century Therapeutics (IPSC) Non-Current Deferred Tax Liability (2022 - 2025)

Historic Non-Current Deferred Tax Liability for Century Therapeutics (IPSC) over the last 3 years, with Q3 2025 value amounting to $4.4 million.

  • Century Therapeutics' Non-Current Deferred Tax Liability rose 2486.44% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 2486.44%. This contributed to the annual value of $4.4 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Century Therapeutics' Non-Current Deferred Tax Liability stood at $4.4 million, which was up 2486.44% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Non-Current Deferred Tax Liability ranged from a high of $4.4 million in Q4 2024 and a low of $5000.0 during Q4 2022
  • Over the past 3 years, Century Therapeutics' median Non-Current Deferred Tax Liability value was $4.4 million (recorded in 2024), while the average stood at $3.5 million.
  • Over the last 5 years, Century Therapeutics' Non-Current Deferred Tax Liability had its largest YoY gain of 2994.65% in 2025, and its largest YoY loss of 2486.44% in 2025.
  • Century Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $5000.0 in 2022, then soared by 87380.0% to $4.4 million in 2024, then changed by 0.0% to $4.4 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $4.4 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.4 million for Q1 2025.